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ABSTRACT 
WNT-CTNN1B signaling promotes cancer cell proliferation and stemness. Furthermore, 
recent evidence indicates that macroautophagy/autophagy regulates WNT signaling. 
Here we investigated the impact of inhibiting WNT signaling on autophagy in 
glioblastoma (GBM), a devastating brain tumor. Inhibiting TCF, or silencing TCF4 or 
CTNNB1/β-catenin upregulated SQSTM1/p62 in GBM at transcriptional and protein 
levels and, in turn, autophagy. DKK1/Dickkopf1, a canonical WNT receptor antagonist, 
also induced autophagic flux. Importantly, TCF inhibition regulated autophagy through 
MTOR inhibition and dephosphorylation, and nuclear translocation of TFEB, a master 
regulator of lysosomal biogenesis and autophagy. TCF inhibition or silencing 
additionally affected GBM cell proliferation and migration. Autophagy induction 
followed by its blockade can promote cancer cell death. In agreement with this notion, 
halting both TCF-CTNNB1 and autophagy pathways decreased cell viability and induced 
apoptosis of GBM cells through a SQSTM1-dependent mechanism involving CASP8 
(caspase 8). In vivo experiments further underline the therapeutic potential of such 
dual targeting in GBM.   
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INTRODUCTION 
Gliomas are primary brain tumors classified into different malignancy grades (World 
Health Organization): diffuse astrocytoma (grade II), anaplastic astrocytoma (grade III) 
and glioblastoma multiforme (GBM; grade IV) [1,2] GBMs are the most common and 
aggressive gliomas, presenting a poor prognosis and median survival below 14 months 
[3]. GBM features are a high infiltrative/invasive capacity, apoptosis resistance, 
necrosis and angiogenesis [4]. Despite treatment (extensive surgery, radiotherapy and 
chemotherapy with temozolomide), GBM recurrence is unfortunately very common. 
Therefore, there is an urgent need for novel therapies for this non-curable disease [5]. 
Canonical WNT signaling plays important functions in development and cell 
proliferation, and its aberrant activation is linked to tumorigenesis [6,7]. The main 
effector of the WNT canonical pathway is CTNNB1/β-catenin [8], which acts together 
with transcription factors of the TCF/LEF (transcription factor/lymphoid enhancer 
binding factor) families to control expression of WNT target genes. In the absence of 
WNT ligands, CTNNB1 associates with the destruction complex that includes GSK3B 
(glycogen synthase kinase 3 beta), a Ser/Thr kinase that phosphorylates CTNNB1, 
leading to its proteasomal degradation. Upon WNT binding to FZD (frizzled class 
receptor) and LRP (LDL receptor related protein) receptors, the destruction complex 
destabilizes. Unphosphorylated CTNNB1 then escapes from degradation and 
translocates to the nucleus [8]. WNT inhibitors, such as the extracellular antagonist of 
LRP5 and LRP6, DKK1/Dickkopf1, control WNT signaling. Unlike other cancers, CTNNB1 
mutations are infrequent in GBM, and WNT signaling activation appears to occur by 
upregulation of WNT ligands [9] or epigenetic regulation of WNT inhibitors [2,10]. 
Additional mechanisms include control by upstream protoncogenes [11], 
overexpression of the scaffold protein DVL2/Dishevelled2 [12] and activation of 
CTNNB1 nuclear signaling [10,13]. 
Macroautophagy (referred to as autophagy) is a conserved adaptive response 
that recycles cellular components to provide nutrients under metabolic cell stress. 
During autophagy, double-membrane vesicles, phagophores, engulf damaged proteins 
and organelles. After maturation into autophagosomes, these compartments then fuse 
with lysosomes, where the cargo is degraded, providing biosynthetic and energy 
precursors, thus contributing to the survival of tumor cells in unfavorable conditions 
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[14]. Autophagy in cancer plays a dual role. In early stages of tumorigenesis, it acts as a 
tumor suppressor preventing accumulation of damaged proteins and organelles. 
However, in advanced stages, autophagy provides tolerance against metabolic stress 
under conditions of nutrient deprivation and confers resistance to radio and 
chemotherapy [15]. MTOR (mechanistic target of rapamycin) regulates cell growth, 
proliferation and anabolic processes, and its inhibition is central to autophagy 
induction [16]. 
Interestingly, autophagy and WNT-CTNNB1 signaling appear inversely regulated 
in cancer. The WNT pathway component DVL2 maintains GBM cell proliferation 
through canonical and noncanonical WNT signaling [12]. In turn, autophagy negatively 
regulates WNT signaling by promoting DVL2 [17] and CTNNB1 degradation [18,19] . 
Furthermore, the TCF-CTNNB1 complex represses SQSTM1/p62 [18], which is 
responsible for the binding to MAP1LC3/LC3 (microtubule associated protein 1 light 
chain 3) that, once lipidated, associates with phagophores and is involved in cargo 
recognition [20]. Finally, WNT signaling (involving GSK3B inhibition) activates MTOR 
and protein translation [21]. 
Here we sought to elucidate the effects of inhibiting WNT-CTNNB1 signaling on 
autophagy in GBM cell lines and biopsy-derived cell cultures. To this end, we inhibited 
TCF-CTNNB1 signaling using the pharmacological inhibitor FH535, silencing TCF4 or 
CTNNB1 by shRNA/siRNA, or challenging the cells with the WNT receptor antagonist 
DKK1. We found that inhibition of WNT signaling in GBM upregulates SQSTM1 and, 
consequently, autophagic flux through MTOR inhibition and nuclear translocation of 
TFEB (transcription factor EB), a master regulator of autophagosome and lysosome 
biogenesis [22,23]. Moreover, our data show that autophagy induction renders GBM 
cells more sensitive to cell death by autophagy blockers, which could be exploited in 
future therapies.  
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RESULTS 
SQSTM1 levels increase in GBM and inversely correlate with CTNNB1  
To test SQSTM1 protein levels in diffuse astrocytoma, anaplasic astrocytoma and GBM 
(grade IV) samples, we performed an immunohistochemical analysis in tissue 
microarrays (TMAs). SQSTM1 was detectable in grade II astrocytomas and its levels 
increased in GBMs (8.78 fold, GBM vs. astrocytomas; p=0.003) (Fig. 1A and 1D). 
Further analysis using the GlioVis platform [24] confirmed the increase of SQSTM1 
mRNA levels in GBMs compared to non-tumor or astrocytoma samples (p<0.001; Fig. 
1B). 
Previous studies in colorectal carcinoma cells [18] described an inverse 
relationship between SQSTM1 and CTNNB1. Data obtained from Gliovis supported this 
in GBM (Fig. 1C; p=0.01), which was corroborated in our GBM biopsy-derived cell 
cultures and established cell lines (Fig. 1D). A comparison of autophagic markers and 
the levels of CTNNB1 or CCND1 (cyclin D1; a WNT target) indicated an inverse 
relationship in several GBM cases (Fig. 1E), further suggesting a negative association 
between WNT-CTNNB1 signaling and autophagy or vice versa.    
 
WNT-CTNNB1 signaling regulates SQSTM1 through TCF-dependent transcriptional 
regulation 
To investigate how WNT-CTNNB1 signaling modulates SQSTM1, GBM cell lines were 
treated with WNT3A to activate WNT-CTNNB1 signaling or with FH535 (a TCF inhibitor 
that affects CTNNB1 recruitment) [25] to inhibit it. WNT3A decreased SQSTM1 mRNA 
in the A172 cell line (Fig. 2A and see below). On the contrary, SQSTM1 expression (at 
both the mRNA and protein levels) increased after treatment with FH535 in U251-MG 
and U87-MG cell lines and in GBM primary cultures (Figs. 2A and 2B). We confirmed 
that WNT3A and FH535 activate or inhibit WNT signaling, respectively, by the TOP-
Flash assay and expression of the target gene CCND1 (Fig. S1). A172 cells displayed 
higher SQSTM1 protein levels than U251-MG or U87-MG cells (Fig. S2), which may 
explain why SQSTM1 could not be further increased by FH535, but significantly 
decreased upon treatment with WNT3A. To validate the results obtained using a 
pharmacological inhibitor of TCF, we transduced cells with lentiviruses carrying a 
shRNA targeting TCF4. Cells expressing the shRNA against TCF4 showed a 60-80% 
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decrease in TCF4 mRNA, compared to cells expressing a scrambled shRNA (Fig. 2C). 
Parallel to this, cells expressing the shRNA of TCF4 increased SQSTM1 mRNA (1.8-2.3 
fold vs. scrambled; Fig. 2C) and SQSTM1 protein levels (Fig. 2D), consistent with the 
FH535 results. Thus, TCF inhibition or silencing raise SQSTM1 expression in GBM cells.  
Because CTNNB1 acts together with TCF, we next investigated the role of 
CTNNB1 in SQSTM1 regulation. First, we transfected GBM cells with siRNAs against 
CTNNB1 or GAPDH (used as a control). We observed decreased CTNNB1 and increased 
SQSTM1 levels in U251-MG and U87-MG cells upon transfection of the CTNNB1 siRNA 
(Fig. 2E). By contrast, cells expressing a stabilized mutant form of CTNNB1 (S37Y) that 
is not degraded, presented lower levels of SQSTM1 compared to cells transfected with 
wild-type (WT) CTNNB1 (Fig. 2F). Together, these results confirm that CTNNB1-TCF 
signaling transcriptionally represses SQSTM1 in GBM. 
 
Inhibition of WNT-CTNNB1 signaling increases the autophagic flux in GBM 
Next, we aimed to understand the functional implications of the SQSTM1 regulation by 
WNT-CTNNB1 signaling. As SQSTM1 acts as a cargo receptor of phagophores, we 
studied the autophagic flux upon inhibition of WNT signaling. First, we reduced the 
activity of TCF with FH535. Analysis of autophagy markers showed an increase of 
MAP1LC3A/B-II in treated cells, indicative of increased autophagosome numbers. 
These results were paralleled by lower levels of polyubiquitinated proteins in GBM 
cells treated with FH535 (Fig. 3A), suggesting an enhancement of autophagy. To 
confirm whether the deregulation observed corresponds to an induction of autophagic 
flux, we used bafilomycin A1 (Baf), which prevents autophagosome-lysosome fusion 
and blocks autophagic flux. Increased autophagic flux would elevate MAP1LC3A/B-II 
upon addition of Baf. If the increase in MAP1LC3A/B-II in treatment plus Baf is higher 
than that of Baf alone, results should be interpreted as autophagic flux induction. 
Instead, MAP1LC3A/B-II levels unaltered by Baf should be interpreted as autophagy 
blockade and accumulation of autophagosomes [26]. We treated GBM cells with or 
without FH535 for 24 h together with Baf (last 2 h). Treatment with FH535 and Baf 
showed higher levels of MAP1LC3A/B-II compared to Baf alone (Fig. 3B), indicating 
autophagy induction by FH535. Importantly, similar results were obtained in GBM 
8 
 
primary cultures (Fig. 3B). These results showed that autophagic flux is augmented by 
inhibition of TCF in GBM.  
To assess the involvement of WNT signaling in autophagy regulation at an 
upstream level of the WNT-CTNNB1 pathway, we treated GBM cell lines with DKK1 (a 
WNT antagonist acting at the receptor level). We treated cells with DKK1 alone or 
together with Baf. Results showed increased MAP1LC3A/B-II levels in cells cotreated 
with DKK1 and Baf compared to cells treated with Baf alone (Fig. 3C), showing that 
DKK1 induced autophagy.   
The regulation of autophagy by inhibition of WNT signaling was additionally 
addressed by transfecting with a tandem-fluorescent tagged MAP1LC3B plasmid 
(ptfLC3/mRFP-EGFP-LC3) [27]. Autophagosomes formed from phagophores that 
incorporated ptfLC3 appear yellow (as a result of the colocalization of mRFP and EGFP 
fluorescence), which distinguished them from autolysosomes (presenting a red 
fluorescence due to quenching of EGFP in the lysosomes). Rapamycin (an MTOR 
inhibitor) increased the number of red puncta (Fig. 3D). In contrast, treatment with the 
autophagy blocker chloroquine (CQ) elevated the number of yellow puncta (Fig. 3D). 
FH535 or DKK1 produced a red puncta pattern, similar to that obtained with 
rapamacyin, demonstrating increased numbers of autolysosomes and autophagy 
induction (Fig. 3D). A comparison of the pattern obtained after FH535 plus CQ vs. 
FH535 alone confirmed an intact autophagic flux (data not shown).   
Finally, we used immunocytochemistry against SQSTM1 and MAP1LC3A 
proteins to study autophagy regulation upon TCF inhibition. Immunostainings from 
cells treated with FH535 were compared to those achieved after treatment with 
rapamycin or with CQ and Baf. Rapamycin moderately increased the number of 
MAP1LC3A and SQSTM1 puncta, as a result of elevated autolysosome numbers caused 
by autophagy induction. Furthermore, CQ or Baf produced a huge increase in 
MAP1LC3A and SQSTM1 puncta, and these appeared bigger, suggesting that they 
corresponded to the fusion of autophagosomes caused by autophagy blockade. 
Interestingly, FH535 moderately increased the number of SQSTM1 and MAP1LC3A 
puncta, similar to rapamycin (Fig. S3). To demonstrate that the increase in SQSTM1 
and MAP1LC3A puncta is due to an induction of autophagy, we also performed the 
MAP1LC3A and SQSTM1 immunostainings under FH535 and CQ combined treatments. 
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Results showed higher increases in the numbers of MAP1LC3A and SQSTM1 puncta 
when comparing the increase in FH535 and CQ cotreatment vs. CQ alone with that 
obtained in FH535 vs. control (Fig. 4). Together, our results demonstrate that inhibition 
of WNT-CTNNB1 signaling, through DKK1 or TCF inhibition, promotes autophagic flux 
in GBM. 
 
Inhibition of TCF diminishes MTOR signaling and produces TFEB nuclear translocation 
The Ser/Thr kinase MTOR occupies a central position integrating positive and negative 
stimuli that trigger autophagy [16,28]. We asked whether TCF inhibition leads to 
autophagy via inhibition of MTOR. U251-MG and U87-MG cells treated with FH535 
showed reduced phosphorylation of RPS6KB/p70S6K and of EIF4E, as well as reduced 
expression of ATF4, all established MTOR substrates (Fig. 5A) [28,29]. On the contrary, 
total levels of RPS6KB and EIF4E were not affected (Fig. 5A). These results indicate that 
MTOR is inhibited upon FH535 treatment. Similar results were obtained by treating the 
cells with the MTOR inhibitor rapamycin, which abolished RPS6KB phosphorylation 
(Fig. 5A). AKT and MAPK/ERK proteins positively regulate the activity of MTOR by 
phosphorylating and inhibiting TSC1/2 [16]. Thus, inhibition of AKT and MAPK 
decreases MTOR activity and promotes autophagy. In line with this, FH535 decreased 
the phosphorylation of AKT and MAPK in U87-MG cells, but not in the U251-MG cell 
line (Fig. 5A). These results suggest that TCF inhibition decreases MTOR activity to 
induce autophagy, through AKT and MAPK in U87-MG cells.  
TFEB is a master regulator that controls lysosomal biogenesis by upregulating 
genes of the Coordinated Lysosomal Expression and Regulation network and 
autophagy, including SQSTM1 [28,30]. When nutrients are present, TFEB colocalizes 
with the MTOR complex on the lysosomal membrane, and phosphorylation of TFEB by 
MTOR inhibits TFEB activation. Nutrient starvation or pharmacological inhibition of 
MTOR activates TFEB (generating dephosphorylated TFEB) by promoting its nuclear 
translocation [28,31,32]. We hypothesized that the mechanism by which TCF inhibition 
induces autophagy could involve TFEB nuclear translocation and, subsequently, 
SQSTM1 upregulation. To investigate the effect of TCF inhibition on TFEB, we analyzed 
lysates of cells treated with FH535 or deprived of serum. In basal conditions, TFEB 
immunoblot showed 2 bands that correspond to the phosphorylated form (upper 
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band) and to the dephosphorylated form (lower band; as confirmed by alkaline 
phosphatase [AP] treatment) (Fig. 5B) [31,32]. Moreover, under deprivation the lower 
dephosphorylated band prevails, as expected (Fig. 5B). Interestingly, GBM cells treated 
with FH535 mostly displayed the TFEB lower band, similar to the deprivation condition 
(Fig. 5B). Quantification of the dephosphorylated:phosphorylated TFEB ratio 
(lower:upper bands) confirmed that TCF inhibition and deprivation significantly 
increased the proportion of the lower band (Fig. 5B). These results suggest that TCF 
inhibition reduces MTOR activity and promotes TFEB dephosphorylation, which has 
been linked to its activation [22,30,31]. We next examined whether TFEB 
dephosphorylation associated with its nuclear translocation. We observed that under 
control conditions TFEB localized in the cytoplasm. However, interestingly, after 
deprivation or FH535 treatments, TFEB was markedly nuclear in GBM cell lines and 
primary cultures (Fig. 5C, 5D and S4). Together, these results indicate that inhibition of 
TCF induces autophagy through MTOR inhibition and TFEB 
dephosphorylation/activation. As TFEB activation controls SQSTM1 expression, these 
results suggest a mechanism for SQSTM1 upregulation by FH535 leading to increased 
autophagy.  
 
TCF inhibition decreases GBM cell proliferation and migration  
Autophagy and cell proliferation are subject to a complex regulation, whereby MTOR 
links both processes by positively regulating cell growth and proliferation and 
negatively affecting autophagy. Furthermore, oncogenic WNT-CTNNB1 signaling is 
involved in cell proliferation and increases MTOR activity [12,21,33]. We examined the 
effects of TCF inhibition or autophagy blockade on cell proliferation by treating GBM 
cell lines with FH535, Baf or CQ. Trypan blue exclusion counting indicated that all 
treatments decreased the number of live cells (Fig. 6A). Next, immunostaining against 
the proliferation marker MKI67/Ki67 further showed a decrease in cell proliferation by 
the 3 treatments, compared to control cells (Fig. S5A). Furthermore, we studied the 
effects of TCF4 gene silencing on U87-MG cell proliferation in a series of lentiviral-
driven shRNA experiments. Both trypan blue assays (Fig. 6B) and MKI67 
immunostaining (Fig. S5B) showed decreased proliferation of shRNA-TCF4 cells 
compared to control cells (scr shRNA), in agreement with the results obtained with 
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FH535. In addition, clonogenic assays showed a significant decrease in the capacity to 
form colonies of TCF4-silenced cells compared to control cells (Fig. 6C).  
The effect of FH535 on GBM cell migration was also explored based on the well-
known involvement of WNT signaling in this process [34]. The effects of FH535 were 
compared to those of Baf and CQ in wound-healing assays. FH535 reduced cell 
migration into the wound area by approximately 50% and 30% in U251-MG cells and 
U87-MG cells, respectively, vs. controls (Fig. S6A). Consistently, similar results were 
obtained in TCF4-silenced U87-MG cells (Fig. S6B). However, treatment with Baf or CQ 
did not significantly affect cell migration. Together, our results indicate that FH535 
reduces GBM cell proliferation and migration.  
 
Dual inhibition of TCF and autophagy promotes GBM cell apoptosis by a SQSTM1-
dependent CASP8 activation  
TCF inhibition/silencing led to autophagy induction accompanied by decreased cell 
proliferation. Upregulating and then blocking autophagy can induce cancer cell death. 
In GBM cells, treatment with FH535 or with autophagy blockers (Baf or CQ) alone 
reduced cell proliferation (Fig. 6A and 6D) and only modestly affected cell viability 
(Figs. 6E and S5C). Interestingly, the combined treatment (FH535 and autophagy 
blockers) reduced cell viability to approximately 20-40% compared to controls (Fig. 6E 
and 6D). Similar results were obtained when TCF4-silenced cells were treated with 
autophagy blockers (Fig. 6F).  
We next sought to determine whether this decrease in cell viability was due to 
cell proliferation or cell death effects. We performed ANXA5 (annexin A5)-propidium 
iodide (PI) assays to assess cell death in GBM cells treated with FH535 or with 
autophagy blockers alone or in combination. Whereas single treatments did not induce 
major effects, the combined treatments (FH535 and Baf or CQ) notably increased the 
percentage of cells in late apoptosis and reduced the number of live cells (Fig. 7A and 
S7A). These results were confirmed by Hoechst staining that demonstrated the 
presence of condensed nuclei in combined treatments, but not in single treatments 
(FH535 or Baf and CQ alone; Fig. 7B).  
Autophagy plays a role in CASP8/caspase8 activation and apoptosis [35,36]. To 
elucidate whether apoptosis induced by the dual FH535 plus Baf and CQ treatment 
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was mediated by CASP8, cell lysates from single or dual treatments were 
immunoblotted for CASP8. As expected, a band compatible with a CASP8 cleavage 
product (p18) was obtained in combined but not in single treatments (Fig. 7C). To 
further elucidate the involvement of CASP8, U87-MG glioma cells were transduced 
with lentiviruses carrying a shRNA targeting CASP8. Interestingly, CASP8-silenced cells 
treated with FH535 and Baf showed a reduction of the percentage of apoptotic cells 
compared to cells expressing CASP8. These results suggest that, in part, CASP8 
mediates the apoptotic cell death caused by the dual treatment with FH535 and Baf 
(Fig. 7D and S7B).  
A role for SQSTM1 in the activation and cleavage of CASP8 in autophagosomes 
has been previously described [35]. To investigate whether SQSTM1 is required for cell 
death, we performed ANXA5-PI staining in control and GBM cells depleted of SQSTM1 
and treated with the different drugs. As expected, FH535 plus Baf caused apoptosis in 
control cells. However, importantly, the apoptotic population was absent in SQSTM1-
silenced cells, indicating that SQSTM1 is needed for apoptosis induction (Fig. 7E and 
S7C). Finally, to confirm that both autophagy induction and blockade were needed to 
induce cell death by the dual treatment, experiments using ATG5-silenced cells were 
performed. ATG5-depleted cells showed the upregulation of SQSTM1 upon FH535 
treatment, as expected (Fig. 8A). However, the cell death induced by the dual 
treatment (FH535 plus Baf) was inhibited in ATG5-depleted cells (i.e., in the absence of 
canonical macroautophagy; Fig. 8C). Together, these results indicate that, by 
upregulating both SQSTM1 and autophagy, FH535 sensitizes GBM cells to autophagy 
blocker-induced cell death. Furthermore, apoptosis appears mediated by the 
accumulation of active CASP8 fragments and depends on SQSTM1 and canonical 
autophagy.   
 
Silencing TCF4 together with CQ administration reduces tumor growth in vivo  
We finally investigated the effect of TCF4-silencing together with CQ treatment in vivo. 
First, we evaluated the anti-tumoral effects of silencing TCF4 in tumor growth. Control 
or TCF4-silenced U87-MG cells were xenografted into SCID mice. TCF4-silenced cells 
formed tumors significantly smaller than control cells, demonstrating the important 
role of TCF4 in tumor growth (Fig. 9A). MKI67 immunostaining showed decreased 
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numbers of MKI67-positive cells in TCF4-silenced tumors compared to controls (Fig. 
9C). Furthermore, SQSTM1 immunostaining presented higher cytoplasmic SQSTM1 
immunoreactivity in TCF4-silenced tumors than in controls, confirming in vitro results 
(Fig. 9C).  
Next, we assessed the synergistic anti-tumoral effects of silencing TCF4 and 
blocking autophagy by CQ treatment. Once tumors were formed, xenografted SCID 
mice were injected intraperitoneally either with CQ or vehicle. CQ treatment did not 
significantly affect growth of control tumors. However, CQ produced synergistic anti-
tumoral effects in TCF4-silenced tumors (Fig. 9B), in agreement with our in vitro 
results. MKI67 immunostaining did not show differences with CQ treatment (Fig. 9C). 
Immunostaining against SQSTM1 in CQ-treated control tumors showed a marked 
punctate pattern, indicating autophagosome accumulation. Interestingly, SQSTM1 
immunostaining in TCF4-silenced tumors treated with CQ showed strong cytoplasmic 
and punctate staining (Fig. 9C). Altogether, these results demonstrate that targeting 
TCF4 and autophagy flux reduces tumor growth, probably through cell death induction 
mediated by upregulated SQSTM1.  
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DISCUSSION  
Since aberrant activation of WNT-CTNNB1 signaling was linked to cancer, designing 
small molecules and strategies to target this pathway has been the focus of 
pharmaceutical and research teams [6,7,37]. FH535 was identified as a TCF-CTNNB1 
inhibitor with anti-proliferative actions [25]. Here we have addressed whether TCF 
inhibition could halt GBM progression. Moreover, the repression of SQSTM1 (a key 
autophagy gene) by TCF-CTNNB1 [18] prompted us to evaluate the consequences of 
inhibiting TCF in autophagy. Our work shows that inhibiting WNT signaling (either using 
the pharmacological inhibitor FH535 or by gene silencing of TCF4 and CTNNB1) 
upregulates SQSTM1 in GBM. A stable mutant of CTNNB1, on the contrary, reduces 
SQSTM1 expression. Therefore, autophagic flux increases upon TCF-CTNNB1 inhibition 
because of SQSTM1 upregulation [38]. Furthermore, inhibition of TCF-CTNNB1 
signaling associates with decreased MTOR activity and translocates TFEB to the 
nucleus, further enhancing autophagy. Importantly, enhancing autophagic flux by 
means of TCF-CTNNB1 inhibition sensitizes GBM cells to autophagy blockers. Thus, 
dual targeting of TCF and autophagy induces GBM cell death and reduces tumor 
growth. 
SQSTM1 is an essential protein in the autophagic process, acting as a cargo 
receptor in phagophores. Because SQSTM1 is degraded by autophagy, its levels often 
inversely relate with autophagic flux [39]. However, multiple pathways regulate 
SQSTM1 expression [40,41], which hinders the interpretations of SQSTM1 levels. 
SQSTM1 increases in GBM cell lines, GBM biopsies and patient-derived cell cultures 
compared to low-grade gliomas. These results suggest that autophagy is higher in GBM 
than in astrocytoma and normal CNS tissue [42]. Similarly, Gao et al. [17] reported 
higher SQSTM1 levels in late-stage colon cancer compared to early stages of the 
disease. In addition, SQSTM1 and DVL correlated, indicating that autophagy negatively 
regulates WNT signaling through DVL and CTNNB1 clearance [17,18,43]. Our results 
suggest a similar scenario: high levels of CCND1 are present in GBMs displaying low 
SQSTM1 and/or BECN1. By de-repressing SQSTM1 using FH535 (which affects the TCF-
CTNNB1 interaction) or by silencing either TCF4 or CTNNB1 [44], both SQSTM1 
expression and autophagic flux increase. This conclusion is attained by the use of Baf in 
the analysis of SQSTM1 and MAP1LC3A/B, and by flux experiments with a MAP1LC3A 
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tandem construct. Remarkably, autophagic flux is also enhanced by DKK1, indicating 
that interfering with WNT canonical receptors positively affects autophagy. 
Interestingly, DKK3 was identified as a biomarker elevated in supernatants of highly 
autophagic melanoma cell lines and in patient sera [45]. Together, our results 
demonstrate that inhibiting WNT signaling triggers autophagy while, conversely, 
autophagy reduces WNT signaling [17,18]. This cross-regulation illustrates a complex 
involvement of both WNT signaling and autophagy in tumor initiation, progression and 
recurrence.  
We have examined the mechanism involved in autophagy elevation by TCF-
CTNNB1 inhibition by analyzing MTOR activation. WNT signaling through GSK3B 
activates the MTOR pathway to stimulate protein translation [21]. Consequently, 
inhibition of TCF decreases MTOR signaling, as indicated by different MTOR targets. 
TFEB has recently emerged as a master regulator of autophagy and lysosomal 
biogenesis, promoting the expression of SQSTM1 and LAMP1 among other targets 
[22,23,28,46]. Under starvation, MTOR inactivation triggers TFEB activation 
(dephosphorylation) and its nuclear translocation [32,47]. Herein, we demonstrate 
that autophagy induction by FH535 (like that promoted by serum deprivation) involves 
the dephosphorylation and nuclear translocation of TFEB in GBM cell lines and biopsy-
derived cultures. These findings provide mechanistic insights into autophagy 
upregulation through WNT-CTNNB1 signaling inhibition.  
Inhibiting/silencing TCFs reduces GBM cell proliferation and tumor growth, in 
agreement with the pro-proliferative role of the WNT-CTNNB1 pathway [33,48]. 
Tumors formed by TCF4-silenced GBM cells are smaller and display less MKI67-positive 
cells than those originated by control cells. In addition to the impact on cell 
proliferation, inhibiting TCF reduces GBM cell migration in a wound-healing assay. 
GBM patients present poor prognosis, in part due to recurrences that originate from 
highly invasive cells. Together, our findings suggest that interfering with TCF function 
using molecules that pass the blood-brain barrier could help in controlling GBM growth 
and progression. However, they also indicate that targeting WNT signaling alone in 
GBM could favor pro-survival/adaptative responses that underlie resistance and 
recurrence.  
16 
 
More important, dual inhibition of TCF and autophagy induces GBM cell death. 
In agreement with this, autophagy induction by temozolomide sensitizes to GBM cell 
death by autophagy blockers [49-51]. The phagophore membrane can serve as a 
platform to mediate CASP8 activation and to initiate the cascade of caspases leading to 
apoptosis [36]. Here we find that the dual treatment results in CASP8 cleavage. 
Furthermore, using SQSTM1- or CASP8-silenced cells, we demonstrate that the cell 
death mechanism involves the cleavage of CASP8, likely located in phagophores, in 
turn mediated by increased SQSTM1 [35] that results from TCF-CTNNB1 inhibition. 
Thus, cells depleted of SQSTM1 remain protected from the cell death induced by the 
combined treatment (TCF inhibitor plus Baf). Moreover, cells depleted of ATG5 are also 
protected, indicating that both autophagy induction and blockade are required in this 
process. Furthermore, these experiments rule out a nonautophagic apoptotic function 
of SQSTM1. In vivo xenograft experiments further illustrate the critical regulation of 
SQSTM1. Tumors formed by TCF4-silenced cells display strong cytosolic SQSTM1 
immunostaining, denoting its upregulation. Tumors formed by TCF4-silenced cells and 
treated with CQ show dotted SQSTM1 immunostaining, due to the blockade of a 
robust autophagic flux, and are smaller than their controls.  
Collectively, we propose that TCF-CTNNB1 inhibition acts in 2 possible ways to 
increase SQSTM1 and autophagy flux in GBM: de-repressing SQSTM1 and inhibiting 
MTOR that leads to TFEB activation (Fig. 9D). According to shRNA experiments, 
SQSTM1 upregulation appears key to promote GBM cell death by autophagy blockers. 
Thus, combined inhibition of TCF-CTNNB1 and autophagy could provide novel 
therapeutic approaches for GBM.  
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Materials and Methods 
Reagents and antibodies 
Biochemical reagents used were from the following companies: rapamycin (Sigma-
Aldrich, R8781), puromycin (Sigma-Aldrich, P7255), CQ (Sigma-Aldrich, C6628), FH535 
(Sigma-Aldrich, F5682), WNT3A (Peprotech, 315-20), DKK1 (Peprotech, 120-45) and Baf 
(Santa Cruz Biotechnology, sc-201550).  
Antibodies were used against the following: CTNNB1 (BD Biosciences, 610153), 
CCND1 (BD Biosciences, DCS-6; 556470), MAPK (BD Biosciences, 610124), SQSTM1 
(Novus Biologicals, NBP1-48320), BECN1 (Novus Biologicals, NB110-87318), 
MAP1LC3A/B (Novus Biologicals, NB100-2331), TFEB (Bethyl Laborathories, A303-
673A), p-AKT (Cell Signaling Technology, 9271S), p-MAPK (Cell Signaling Technology, 
9107), p-RPS6KB (Cell Signaling Technology, 2055), total RPS6KB (Cell Signaling 
Technology, 9202), ATF4 (Cell Signaling Technology, D4B8), AKT (Santa Cruz 
Biotechnology, sc-1618), CASP8 (Calbiochem, AM46), p-EIF4E (Millipore, 07-823), total 
EIF4E (GeneTex, GTX132092), ACTB (Sigma-Aldrich, A5441) and ATG5 (Sigma-Aldrich, 
A2859). 
 
Cell culture 
Tumor biopsies were obtained from Hospital Universitari Arnau de Vilanova (Lleida, 
Spain) and processed within 30 min from surgery. All patients signed informed 
consents prior to biopsy collection and the study was approved by the local Ethics 
Committee of Human Experimentation. Primary GBM cultures were established as 
described [13]. Briefly, tissue was washed and digested in phosphate-buffered saline 
(PBS; 137 mM NaCl, 2.7 mM KCl, 1.47 mM KH2PO4 and 4.3 mM Na2HPO4) containing 
155 U/ml of collagenase I (Worthington, LS004194) and 12 mg/ml of DNase-I (Sigma, 
DN25). The cell suspension was filtered and washed before plating in Dulbecco’s 
Minimal Essential Medium (Lonza, BE12-741F) containing 10% fetal bovine serum (FBS; 
Gibco, 10270098).  
GBM cell lines A172, U251-MG and U87-MG were obtained from CLS Cell Lines 
Service (300108, 300385 and 300367, respectively). Cells were maintained in Minimal 
Essential Medium (Lonza, BE12-125F) containing 10% FBS, penicillin/streptomycin 
19 
 
(Gibco, 15140-122), L-glutamine (Gibco, 25030-081), 1% amino acids (Gibco, 11140-
035) and 1% sodium pyruvate (Gibco, 11360-039) at 37°C and 5% CO2 atmosphere. 
 
 
Transfection, MAP1LC3B tandem construct and luciferase assay 
GBM cells were plated the day before transfection at 80% confluency. For knockdown 
with siRNA sequences, RNAimax Lipofectamine (Invitrogen, 13778075) was used. 
Briefly, 25 µl of Optimem (Gibco, 31985-047) containing siRNA (80 nM; Sigma 
VPDSIRNA2D for CTNNB1 and PDSIRNA2D for GAPDH) were mixed with 25 µl of 
Optimem plus 1 µl of RNAimax Lipofectamine. The mix was incubated for 15 min at 
room temperature (RT) and added dropwise to cells for 6 h. Then media was changed 
for complete media (MEM including FBS). For transfection of tandem fluorescent-
tagged MAP1LC3B (ptfLC3), TOP-Flash or WT and S37Y CTNNB1 (kind gifts of Dr A. 
Garcia de Herreros, UPF-IMIM, Barcelona, Spain) plasmids using Lipofectamine-2000 
(Invitrogen, 11668-027), the procedure was as described previously [13]. 
The ptfLC3 plasmid, a kind gift from Dr. T. Yoshimori (University of Osaka, 
Japan) is a MAP1LC3B tandem construct that codes for MAP1LC3B tagged with green 
fluorescent protein (EGFP) and monomeric red fluorescent protein (mRFP) [27]. After 
24 h of transfection, cells were treated with 10 µM FH535, 25 µM CQ or 500 nM 
rapamycin for 24 h. At 48 h (after 24 h of transfection), cells were pictured under an 
epifluorescence microscope and analyzed for colocalization of green and red puncta. 
Quantification of red and green puncta was performed using ImageJ software and the 
pictures obtained from the 2 separate channels (EGFP and mRFP). Therefore, 
autophagy blockade is visualized by similar numbers of overlapping red and green (i.e., 
yellow) puncta in the plots. In contrast, autophagy induction involves the 
predominance of red puncta (reflecting an increase of autolysosomes). 
To determine CTNNB1 transcriptional activation status, a luciferase assay was 
performed following transfection of the TOP-Flash plasmid that carries a synthetic 
promoter containing 3 copies of the TCF4 binding site upstream of a firefly luciferase 
reporter gene, as described elsewhere [13].  
 
Western blot 
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Cells were washed with PBS and lysed in 62.8 mM Tris, pH 6.8, 2% SDS. Cell lysates 
were resolved in 10 to 15% SDS-PAGE gels and transferred to a PVDF membrane 
(Merck-Millipore, IPVH00010). Membranes were blocked with 5% bovine serum 
albumin (Fisher Scientific, BP9701) or milk and incubated overnight with primary 
antibodies in Tris Buffer Saline (20 mM Tris, pH 8, 150 mM NaCl) containing 0.05% 
Tween-20 (Sigma, P1379). Blots were developed using Enhanced Chemiluminiscence 
(ECL; Thermo Scientific, 32106) or Luminata Forte horseradish peroxidase substrate 
(Merck-Millipore, WBLUF0100). Band intensities were normalized against ACTB (used 
as a loading control) using ImageJ software. For TFEB western blot quantification, the 
intensity of the lower and upper band was measured using ImageJ and the ratio 
represented. Quantifications were performed from at least 3 independent 
experiments. For AP (Promega, M282A) treatment, A172 cells were lysed in Igepal 
buffer (150 mM NaCl, 50 mM Tris, pH 8, 1 mM EDTA, 1 mM EGTA, 1% Igepal [Aldrich, 
542334] and Complete protease inhibitors [Roche, 11873580001]). Then, cell lysates 
(approximately 80 µg/condition) were incubated with or without AP (40 U, 30 min, 
37°C) in 50 mM Tris, pH 9.3, 1 mM MgCl2, 0.1 mM ZnCl2, 1 mM spermidine (AP buffer; 
Promega, M183A). The reaction was stopped with Laemmli’s sample buffer.  
 
Immunofluorescence 
Cells were cultured on poly-D-lysine (Sigma, P7280) glass coverslips and fixed with 4% 
paraformaldehyde (Sigma, P1213; 15 min, RT), washed with PBS, blocked and 
permeabilized in PBS containing 5% FBS, 5% horse serum (Gibco, 26050088), 0.2% 
glycine, 0.1% Triton X-100 (Sigma, T8787; or 0.3% in the case of TFEB immunostaining) 
before incubation with primary antibodies. Secondary antibodies were coupled to 
Alexa Fluor 488 (Life Technologies, A11001 or A11008) or Alexa Fluor 594 (Life 
Technologies, A21207 or A11005). Hoechst (Sigma, B2261) was included with the 
secondary antibodies mix to stain nuclei. Coverslips were mounted on Mowiol (Merck, 
475904). Micrographs were obtained using an inverted Olympus IX70 microscope (10x, 
0.3 NA or 10x, 0.4 NA) equipped with epifluorescence optics and a camera (Olympus 
OM-4 Ti). Images were acquired using DPM Manager Software. Quantification of 
nuclear TFEB immunostaining was performed using ImageJ software by scoring the 
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number of cells in which TFEB was colocalizing with Hoechst staining (at least 100 cells 
were counted for each condition from 3 independent experiments). 
 
shRNA-induced gene silencing by lentiviral infection 
Lentiviral-based vectors for RNA interference-mediated gene silencing were pLKO.1-
puro (Sigma-Aldrich), containing shRNAs scrambled (against the sequence 5’ 
CAACAAGATGAAGAGCACCAA 3’), of TCF4 (Mission-RNA; Sigma-Aldrich, 
TRCN0000015037) and SQSTM1 (Mission-RNA; Sigma-Aldrich, TRCN0000007237), or 
FSV vector containing a shRNA of CASP8 [52] and ATG5 (against the sequence 5’ 
CCTTTCATTCAGAAGCTGTTT 3’). Lentiviral particles were produced in HEK293T (human 
embryonic kidney) cells for 72 h upon transfection of the shRNA vectors together with 
psPAX2 and pMD2G plasmids (a kind gift of Dr D. Trono, Lausanne, Switzerland) using 
polyenthyleneimine (Sigma, 408727). Medium was then centrifuged (1000 x g, 5 min) 
and filtered through a 0.45 µm membrane (Millipore, SLHV033RS). Cells were 
incubated with medium containing lentiviral particles for 24 h. Then, medium was 
replaced to allow the knockdown for 4 or more days. pLKO.1-puro vectors contain a 
puromycin resistance site. Puromycin (4 µg/ml; Sigma, P7225) was added to the media 
to select for resistant cells and to generate stable target-deficient GBM cell lines and 
Polybrene (1.75 µg/ml; Sigma, H9268) to enhance viral infection.  
 
Real-time PCR 
RNA was isolated using a Nucleospin RNA isolation kit (Macherey-Nagel, 74095550). 1 
µg of mRNA was reverse transcribed to cDNA (25°C for 10 min, 42°C for 1 h and 95°C 
for 5 min) using Superscript II reverse transcriptase (Applied Biosystems, 4308228). 
cDNA (1 µl) was analyzed by quantitative PCR (qPCR; ABI Prism 7000HT, Applied 
Biosystems). Assays were based on TaqMan hydrolysis probes labeled with FAM 
(Applied Biosystems, references are indicated below). Gene-specific probes for 
SQSTM1 (Hs00177654_m1), TCF4 (Hs00162613_m1) and GAPDH (as control, 
Hs99999905_m1) were selected from Applied Biosystems. Samples were assayed in 
triplicate for each gene and relative expression calculated by the ΔΔCT method 
(Applied Biosystems). 
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Wound healing assay 
GBM cells were plated in 24-well plates and cultured to 100% confluency. A wound 
was created by scraping the cell monolayer with a 200-µl pipette tip. Cells were then 
treated as indicated. Cell migration into the wound area was recorded by picturing the 
wound area at 0 and 24 h in 6 selected microscopy fields for each condition and time 
point. The distance travelled by cells was calculated by measuring the wound width 
using ImageJ. 
 
Cell viability assay  
Cell viability was measured by the WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-  
tetrazolio]-1,3-benzene disulfonate; Roche, 05015944001) colorimetric assay. Cells 
were plated on 96-well plates (5000 cells/well), treated for 48 h and then incubated for 
60–120 min with 0.5 mg⁄ml WST-1. Absorbance was measured at 440 nm using a 
reference filter at 620-nm wavelength in a microplate reader (Bio-Rad Laboratories). 
Viability assays were performed in at least 3 independent experiments, using triplicate 
measurements per condition. 
 
Clonogenic assays 
For clonogenic assays, 500 cells/well were plated in 6-well plates. Cells were incubated 
for 10 days and stained with MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide, 0.5 mg/ml; Sigma, M2128). Colony numbers were counted using the Cell 
Counter ImageJ plugin. 
 
Apoptosis analysis 
For nuclear staining, cells were incubated with Hoechst (5 μg/ml, 15 min) and 
condensed nuclei counted under an epifluorescence microscope. For ANXA5-PI 
staining, cells were trypsinized, washed in PBS and centrifuged (200 x g, 5 min). Cells 
were stained (15 min, RT) with ANXA5-FITC or -APC (Immunotools, 31490013 or 
31490016) and PI (0.02 mg/ml; Sigma, P4170). The percent of apoptotic cells was 
evaluated using a FACSCanto II flow cytometer (BD Biosciences). For each condition 
20,000 cells were recorded in 3 independent experiments. 
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Xenografts 
Severe Combined Immunodeficient (SCID) mice (12-weeks old; 20-25 g; maintained in 
Specific Pathogen Free conditions in the Animal House of UdL-IRBLleida) were 
subcutaneously injected with TCF4-deficient or control (scrambled shRNA) U87-MG 
cells (3x106 cells) suspended in 50 µl of PBS. The study was approved by the local 
Ethics Committee of Animal Experimentation. Tumors were allowed to grow for 30 
days. Xenografted mice were treated with intraperitoneal daily injections of CQ (25 
mg/kg) or vehicle (PBS; approximately 150 µl) during 2 consecutive weeks and tumors 
measured every 2 days using a caliper. Tumor size was calculated using the formula: 
tumor weight (mg) = (Dxd2)/2= mm3. 
 
Immunohistochemistry  
Two tissue microarrays (TMAs) were constructed [13] including a total of 74 brain 
tissue samples: 7 samples of grade II astrocytomas, 10 samples of grade III 
astrocytomas and 57 samples of GBMs, which were formalin fixed and paraffin 
embedded. Samples were obtained with support by IRBLleida-Biobank (B.0000682) 
and Plataforma Biobancos (PT13/0010/0014). 
Animal and human paraffin blocks were sectioned and slides prepared for 
immunohistochemistry. The procedure of deparaffinization, rehydration, epitope 
retrieval, and staining was performed as described [13]. The primary antibodies used 
were against SQSTM1 (1:3000 dilution; Novus Biologicals, 48320) and MKI67 (Ready to 
Use; DAKO, IR626). Immunoexpression was graded semi-quantitatively by considering 
the percentage and intensity of the staining. A histological score was obtained from 
each sample, ranging from 0 (no immunoreaction) to 300 (maximum 
immunoreactivity) [13,53].  
 
Gliovis and statistical analysis 
Glioma expression data of the REMBRANDT and TCGA dataset were analyzed through 
the GlioVis portal (http://gliovis.bioinfo.cnio.es) [24]. All experiments are represented 
as mean ± s.e.m. Student’s t-test was performed. * indicates p<0.05; ** p<0.01; ***p< 
0.001. 
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Abbreviations 
AP, alkaline phosphatase  
ACTB, actin beta 
CTNNB1/β-catenin, catenin beta 1 
Baf, bafilomycin A1 
CQ, chloroquine 
DKK1, dickkopf WNT signalling pathway inhibitor 1 
DVL2, dishevelled segment polarity protein 2 
FBS, fetal bovine serum 
GAPDH, glyceraldehyde-3-phosphate dehydrogenase 
GBM, glioblastoma multiforme 
GSK3B, glycogen synthase kinase 3 beta 
LRP, LDL receptor related protein 
MAPK, mitogen-activated protein kinase 
MTOR, mechanistic target of rapamycin 
MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
PBS, phosphate-buffered saline 
PI, propidium iodide 
SCID, severe combined immunodeficient  
SQSTM1/p62, sequestosome 1 
TCF, T-cell transcription factor 
TFEB, transcription factor EB 
TMA, tissue microarray 
WST-1, 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate 
WT, wild-type
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FIGURE LEGENDS 
Figure 1. SQSTM1 levels increase in GBMs and inversely correlate with CTNNB1. (A) 
Representative immunostainings for SQSTM1 from astrocytoma grade II and GBM 
(grade IV) biopsies from the TMAs. Nuclei were counterstained with haematoxylin. 
Bar: 100 µm. (B) SQSTM1 mRNA levels in non-tumor, astrocytomas (grade II and III) 
and GBM tumors as analyzed by Gliovis platform. ***p<0.001 (Turkey’s statistics). (C) 
CTNNB1 and SQSTM1 expression correlation as analyzed by Gliovis in GBM samples 
(Pearson correlation). (D) Primary cultures from astrocytoma grade II and GBMs grade 
IV, and GBM cell lines were analyzed for SQSTM1 and CTNNB1 by WB. (E) Different 
GBM (grade IV) primary cultures were immunoblotted for autophagic markers, 
CTNNB1 and the WNT target, CCND1. CTNNB1 or CCND1 levels inversely relate with 
autophagic markers (SQSTM1, BECN1 or MAP1LC3A/B-II) in a number of cases. 
ACTB/β-actin was used as a loading control.  
 
Figure 2. WNT-CTNNB1 signaling transcriptionally upregulates SQSTM1 in GBM. (A) 
GBM cell lines were treated with WNT3A (100 ng/ml) and FH535 (10 µM) for 24 h. 
SQSTM1 mRNA levels were analyzed by qPCR and data presented as fold induction vs. 
control normalized to GAPDH. Values are mean ± s.e.m of triplicate measurements of 3 
independent experiments. (B) SQSTM1 immunoblotting analysis in A172, U251-MG 
and U87-MG GBM cell lines and C17 and C65 primary GBM cultures treated with 
FH535 (10 µM, 24 h). ACTB was used as a loading control. (C) TCF4 and SQSTM1 mRNA 
levels were examined by qPCR in control (scrambled shRNA; Scr) or TCF4-silenced 
(shRNA TCF4) U251-MG and U87-MG cell lines. (D) SQSTM1 protein levels in control 
cells (Scr) or TCF4-silenced GBM cell lines. (E and F) A172, U251-MG and U87-MG cells 
were transfected with CTNNB1 or control (GAPDH) siRNAs (E) or with WT and S37Y 
CTNNB1 plasmids (F) and SQSTM1 and CTNNB1 protein levels were analyzed after 48 
h.  *p<0.05, **p<0.01 and ***p<0.001 
 
Figure 3. Inhibition of WNT-CTNNB1 signaling increases the autophagic flux in GBM. 
(A) Total cell lysates from A172, U251-MG and U87-MG cells untreated or incubated 
with FH535 (10 µM, 24 h) were immunoblotted for MAP1LC3A/B and ubiquitinated 
(Ub) proteins. (B and C) U251-MG and U87-MG GBM cell lines and C17 and C65 
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primary GBM cultures (B) were treated with FH535 as above (B) or with 50 ng/ml DKK1 
(C) for 24 h plus Baf (5 nM) for the last 2 h. Cell lysates were immunoblotted for 
MAP1LC3A/B. Values indicate the fold increase of MAP1LC3A/B-II vs. untreated control 
cells. ACTB was used as a loading control. (D) Representative images from U87-MG 
cells transfected with the ptfLC3 plasmid and treated with the indicated drugs. Pictures 
correspond to merge of red and green channels. Cells with red and green colocalizing 
(yellow) fluorescent MAP1LC3A/B puncta show autophagosomes, whereas red-only 
fluorescent MAP1LC3A/B dots indicate autolysosomes. Bar: 50 µm. The numbers of 
green and red puncta/cell were calculated and shown as a bar graph (note that 
whereas in CQ there is a balance between red and green puncta, the other treatments 
show a marked increase of red dots). Data are mean ± s.e.m of at least 40 different 
cells from 10 different fields from 3 independent experiments. *** p<0.001.  
 
Figure 4. TCF inhibition increases SQSTM1 and MAP1LC3A/B puncta in GBM. SQSTM1 
(A) and MAP1LC3A (B) immunostaining in the U87-MG GBM cell line. Cells were 
treated in the absence or presence of FH535 (10 µM, 24 h) and CQ (25 µM, last 2 h). 
Insets show enlarged areas. The number of puncta was counted using ImageJ. Plots 
show the increase in the number of MAP1LC3A (A) and SQSTM1 (B) puncta when 
comparing the FH535 and CQ doubly-treated cells vs. CQ-treated cells to the number 
of puncta obtained in FH535-treated cells vs. untreated cells. **p<0.01. Bars: 20 µm.  
 
Figure 5. Inhibition of TCF diminishes MTOR signaling and promotes TFEB nuclear 
translocation. (A) U251-MG and U87-MG cells were treated with 10 or 20 µM FH535 or 
5 µM rapamycin for 24 h. Western blots for phosphorylated RPS6KB (Thr389), EIF4E 
(Ser209), total RPS6KB, total EIF4E and ATF4 levels were analyzed as MTOR targets. 
Phosphorylated AKT (Ser473) and MAPK (Tyr202/204) were analyzed and compared to 
total AKT and MAPK. ACTB was used as a loading control. Plots represent the 
quantification of phosphorylated RPS6KB, phosphorylated EIF4E and ATF4 levels 
normalized vs. ACTB (shown as percent of the control; *p <0.05 and *** p<0.001; n≥3). 
(B) Immunoblot for TFEB from U251-MG, U87-MG and A172 untreated cells, cells 
treated with FH535 or deprived of serum for 24 h. The TFEB upper band corresponds 
to the phosphorylated/inactive TFEB form, whereas the lower band corresponds to 
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dephosphorylated and active TFEB, as indicated by the deprivation condition. Small 
panels show A172 cell lysates treated with or without AP, demonstrating the TFEB 
band shift towards the lower band in the presence of the enzyme. ACTB was used as a 
loading control. The plot represents the quantification of the 
dephosphorylated:phosphorylated TFEB ratio (lower:upper band) (*p <0.05 and 
**p<0.01; n≥3). (C) TFEB immunostaining (green) overlapped with Hoechst staining 
(blue) in U251-MG and U87-MG cell lines and C65 primary GBM cells, after treatment 
with FH535 or serum deprivation and compared to control cells. Note that in all 
conditions except controls (where TFEB immunostaining appears perinuclear; arrows), 
TFEB immunostaining is predominantly nuclear and colocalizes with Hoechst. Bar: 50 
µm. Single-channel TFEB pictures can also be found Fig. S4. (D) Quantification of 
nuclear TFEB immunostaining in U251-MG, U87-MG and C65 GBM cells treated as 
indicated. *** p<0.001.  
 
Figure 6. TCF inhibition decreases GBM cell proliferation. (A) U251-MG and U87-MG 
cells were treated with FH535 (10 µM), Baf (5 nM) and CQ (15 µM). After 24 and 48 h 
of treatment, cells were counted using trypan blue staining. (B) Control (shRNA scr) 
and TCF4-silenced (shRNA TCF4) U87-MG cells were counted after 24, 48 and 72 h of 
plating. (C) Control (shRNA scr) and TCF4-deficient U87-MG cells were grown in colony-
forming assays and colony numbers counted. Representative images are shown. (D) 
U251-MG and U87-MG cells were treated as indicated for 48 h before cell counting. 
The plot shows the number of cells compared to the respective control at 48 h. The 
dashed line indicates the number of plated cells. FH535 and Baf/CQ treatments 
reduced cell proliferation, whereas the dual treatments reduced the number of cells 
below the line (indicating cell death; see Fig. 7). (E) U251-MG and U87-MG cell viability 
was measured using the WST-1 reagent. Treatments were performed alone or in 
combination for 48 h at the indicated concentrations. * p-value compares to FH535 
alone, and # p-value compares to the autophagy blocker (Baf or CQ) treatment alone; 
* or # p <0.05 and  ** or ## p<0.01. (F) Control and TCF4-deficient U87-MG cells were 
treated with autophagy blockers (Baf and CQ) for 48 h and cells were subjected to the 
WST-1 viability assay. *p<0.05, **p<0.01.  
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Figure 7. Dual inhibition of TCF and autophagy sensitizes to cell death. (A) U251-MG 
and U87-MG cells were analyzed by ANXA5-PI assay to calculate live, early and late 
apoptotic and necrotic cell populations. Cells were treated as indicated for 48 h. 
*p<0.05. (B) U251-MG cells incubated with single or dual treatments as above and 
stained with Hoechst. Condensed apoptotic nuclei are observed after dual treatment 
with TCF inhibitor and CQ. Bar: 50 µm. (C) Immunoblot for CASP8 in U87-MG cells 
shows an active cleaved CASP8 (p18) fragment upon FH535 and Baf double treatment. 
p43 corresponds to a CASP8 pro-fragment [36]. ACTB was used as a loading control. (D) 
ANXA5-PI assay performed in control (empty vector) or in CASP8-silenced cells treated 
with FH535 and Baf for 48 h. (E) ANXA5-PI assay from control U87-MG cells (scr shRNA) 
or shRNA SQSTM1 cells treated as indicated for 48 h (n.s., non significant). (F) 
Immunoblots showing reduced CASP8 (top) and SQSTM1 (bottom) protein levels upon 
expression of specific shRNAs in U87-MG cells. ACTB was used as a loading control. 
  
Figure 8. The cell death induced by the dual inhibition of TCF and autophagy is 
reversed in ATG5-depleted cells. (A) Immunoblot for SQSTM1 from U87-MG cells 
transduced with control lentiviruses or carrying an shRNA against ATG5, untreated or 
treated as indicated. SQSTM1 is upregulated by the FH535 treatment both in control 
and in ATG5-deficient cells. (B) Immunoblot showing reduced ATG5 levels in cells 
expressing shRNA against ATG5 vs. control cells. ACTB was used as a loading control. 
(C) ANXA5-PI assay from control U87-MG cells or cells carrying an shRNA against ATG5, 
untreated or treated with the dual treatment (FH535 + Baf) for 48 h (n.s., non 
significant). *p<0.05 
 
Figure 9. Dual inhibition of TCF and autophagy in vivo reduces tumor growth. (A) 
Representative pictures of mice xenografts formed by control or TCF4-silenced U87-
MG cells. Tumors were allowed to grow for 30 days. Upon mouse sacrifice, tumors 
were collected and prepared for immunostaining. Left, graph of tumor growth over 
time of mice xenografts formed by U87-MG cells (control or TCF4-silenced). Right, 
representative images of tumors from each condition. (B) SCID mice were injected with 
control or TCF-4 silenced U87-MG cells and once tumors were formed, animals were 
treated daily intraperitoneally with CQ (25 mg/kg) or PBS for 15 days. Left, graph of 
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tumor growth over time. Results are mean ± s.e.m. Right, representative images of 
tumors. (C) Immunostaining against MKI67 and SQSTM1 from control or TCF4-silenced 
U87-MG xenografted tumors treated with CQ or vehicle. Bar: 100 µm. *p<0.05, 
***p<0.001. (D) Model for the induction of autophagy upon WNT signaling inhibition 
and GBM cell death by combined targeting of TCF-CTNNB1 and autophagy. Interfering 
with TCF-CTNNB1 function de-represses SQSTM1, which increases autophagic flux and 
decreases proliferation. DKK1 also increases autophagy flux, suggesting that autophagy 
can be regulated from the WNT receptor level. Elevated autophagic flux associates 
with decreased MTOR activity and nuclear translocation of dephosphorylated TFEB 
that can transcribe more SQSTM1. WNT-dependent GSK3B inhibition leads to MTOR 
activation [21]; however, the mechanism by which TCF-CTNNB1 inhibition reduces 
MTOR activity is unknown (dashed arrow). Increased autophagy resulting from TCF 
inhibition elicits GBM cell death by autophagy blockers, through a mechanism that 
requires SQSTM1 and CASP8 cleavage, probably in phagophores. WNT R, WNT 
receptor.  
 









